Market Overview

Alnylam, Tekmira Resolve All Litigation; Alnylam to Make $65M One-Time Payment

Related ALNY
Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now
Alnylam Reports Positive Initial Clinical Results for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) for the Treatment of Acute Hepatic Porphyrias
Julian Robertson Boosts His Stakes in, Netflix (GuruFocus)
Related TKMR
Tekmira Officially Becomes Arbutus Biopharma
5 Biotech Stocks On Deck With The FDA

Alnylam (NASDAQ: ALNY) and Tekmira Pharma (NASDAQ: TKMR) announced a settlement agreement that resolves all litigation between the companies, and has signed a new licensing agreement that restructures the relationship and provides clarity on all intellectual property and licensing issues between the companies. As a result of the restructuring and new agreements, Tekmira will receive $65 million within 10 days and is eligible to receive $10 million in near-term milestone payments expected to be received in 2013.

Posted-In: News Legal


Related Articles (ALNY + TKMR)

Get Benzinga's Newsletters